......
"The first life-extending drug that has undergone three phases of clinical trials has been officially announced. It was jointly developed by pharmaceutical companies such as GlaxoSmithKline, Roche, and AstraZeneca, together with China National Pharmaceutical Group Corporation."
There has been ongoing internal discussion regarding which pharmaceutical company will be responsible for the production and subsequent sales of the longevity-extending drug after its successful development.
Because of the enormous interests involved, especially the concessions made by the Europa League, China owns the patent ownership and sales rights for the entire Greater China region.
In other words, China's share belongs to China, while the shares held by other countries belong to the European Union.
It seems like they didn't gain anything; if the Europa League doesn't renounce these rights, China can also prevent them from entering the Chinese market.
However, that's not how it's calculated. First of all, once the drug is announced, it's impossible to stop it. The Chinese authorities cannot prevent the life-extending drug from entering the Chinese market.
There are too many people who need this, especially the elderly who currently or in the past have more social resources.
Moreover, the Chinese side is actually unaware of the entire production process. They have mastered most of it, but it will take time to completely reverse engineer it.
The concession made by the Europa Union was to give up the complete manufacturing process and the entire Chinese market to China.
Of course, lie detector equipment is only one part of the transaction, not the whole thing.
The struggle among Chinese pharmaceutical groups for ownership of the new drug has also become a major drama.
There are many central enterprises in China's biopharmaceutical field, such as China Resources Pharmaceutical, Yanjing Pharmaceutical, and Sinopharm Holdings.
The reason why Huaguo Pharmaceutical Group was able to win in the end was because they are a wholly state-owned enterprise, meaning that all shares belong to the state.
"The details of this new drug and its clinical trial data will be published in the latest issue of The Lancet. Huaguo Pharmaceutical Group has obtained authorization for the entire Greater China region due to its participation in the specific research and development."
The above are just news reports from within China; on foreign websites, China is only mentioned briefly in a few sentences.
The news quickly became the hottest topic worldwide, with everyone discussing it.
The Europa League also played a role in this.
Following this news, all flights in London were suddenly suspended.
All six airports, including Heathrow, Gatwick, Luton, London City, and Stansted, have suspended all aircraft takeoffs and landings.
London quickly contacted various countries and determined that the entire airspace over London would be designated a no-fly zone, prohibiting all aircraft from taking off or landing in London.
The specific reasons are likely to be guessed by outsiders, but it doesn't matter anymore, because according to sources in London, a large number of unknown people have flooded into the city.
England, and the Europa League behind it, are now trying to resolve this issue before anyone else on Earth can react.
If a solution cannot be found, at least a management mechanism should be developed before the outside world becomes aware of what has happened.
All flights to and from London were suspended. Planes that were originally scheduled to land in London had to land at airports in cities surrounding London and then take public transport to London.
This news, which would have sparked a lot of discussion, was overshadowed by the news of the successful development of a life-extending drug.
Using a news story to confuse the public's memory is a common technique in the field of communication studies.
New news must be sensational enough, and then, with the help of the media, previous hot topics are quickly overshadowed.
The internet's seven-day memory is no joke.
Thanks to the efforts of England and the Europa League, the news of London Airport's closure didn't even cause a ripple for seven days.
Aside from those who recently needed to travel to London and were slightly taken aback, the incident seemed remarkably calm on social media.
If this is the case even in England, one can only imagine how it is in China, thousands of miles away.
Apart from a few Chinese students in London who were planning to return home complaining on TikTok, everyone's attention was focused on the life-extending drug.
"No wonder Sinopharm Holdings has been hitting the daily limit up for four consecutive days. It turns out there's some positive news of this magnitude."
We strongly urge the China Securities Regulatory Commission (CSRC) to conduct a thorough investigation, as this absolutely involves insider information.
"In addition to Sinopharm Holdings, there are also several listed companies under China National Pharmaceutical Group, such as Sinopharm Co., Ltd., Sinopharm Group Co., Ltd., Tiantan Biological Products Co., Ltd., Modern Pharmaceutical Co., Ltd., and Huaguo Traditional Chinese Medicine Co., Ltd."
They're all hitting their daily price limit.
Among them, Huaguo Traditional Chinese Medicine was the first to fall out of the list of stocks hitting the daily limit.
The logic is simple: no matter how good the life-extending drugs are, they are not something that Chinese medicine can offer; they are completely unrelated.
It hit the daily limit for one day after being associated with the concept of life-extending drugs, but then the price stopped rising.
"It all depends on which subsidiary Huaguo Pharmaceutical will allocate the production and sales of the longevity-enhancing drugs to."
It may not be these few listed companies.
"It will definitely be one of Tiantan Biological Products, Modern Pharmaceutical, and Sinopharm."
Sinopharm Holdings is a distributor and supply chain service provider of pharmaceuticals and health products, and it is not very involved in the production and research and development of drugs.
It's less likely that Tiantan Biological is involved, as Tiantan Biological mainly produces blood products.
This includes recombinant human coagulation factors, subcutaneously injected human immunoglobulin, and human prothrombin complex.
Tiantan Biological Products has always focused on blood products, with limited R&D and production capabilities.
"Ultimately, which company will be allocated production and sales will depend on the manufacturing process of the longevity drug."
What if the production of the life-extending drug involves a large amount of blood products?
It's even possible that a large amount of traditional Chinese medicine will be used, and ultimately, the production and sale of this longevity elixir might be allocated to Chinese medicine companies in China.
My dear reader, there's more to this chapter! Please click the next page to continue reading—even more exciting content awaits!
Continue read on readnovelmtl.com
